<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2025.1621781</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Mice mucosal leishmaniasis model shown high parasite load, increased cytotoxicity and impaired IL-10<sup>+</sup> T cell response</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Da-Rocha</surname>
<given-names>Alisson Amaral</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dos-Santos</surname>
<given-names>J&#xfa;lio Souza</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/722063/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bittencourt</surname>
<given-names>Igor Santos</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>De-Almeida</surname>
<given-names>Douglas B.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Manh&#xe3;es</surname>
<given-names>Naiara Carla dos Santos</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Praxedes</surname>
<given-names>Hozany</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/3052812/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Romano</surname>
<given-names>Jo&#xe3;o Victor Paiva</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/3053444/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>da Silva-Junior</surname>
<given-names>Elias Barbosa</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2658862/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>da Silva-Gon&#xe7;alves</surname>
<given-names>Ant&#xf4;nio Jos&#xe9;</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Oliveira</surname>
<given-names>Marcia Pereira</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1373910/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Covre</surname>
<given-names>Luciana Polaco</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/580579/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gomes</surname>
<given-names>Daniel Claudio de Oliveira</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/400559/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Da-Cruz</surname>
<given-names>Alda Maria</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/46564/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>da Fonseca-Martins</surname>
<given-names>Alessandra Marcia</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/435676/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>de Matos Guedes</surname>
<given-names>Herbert Leonel</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/396717/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Instituto de Microbiologia Paulo de G&#xf3;es &#x2013; Universidade Federal do Rio de Janeiro</institution>, <addr-line>Rio de Janeiro, Rio de Janeiro</addr-line>,&#xa0;<country>Brazil</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Laborat&#xf3;rio de Imunologia Cl&#xed;nica, Instituto Oswaldo Cruz, Funda&#xe7;&#xe3;o Oswaldo Cruz</institution>, <addr-line>Rio de Janeiro</addr-line>,&#xa0;<country>Brazil</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Instituto de Biof&#xed;sica Carlos Chagas Filho &#x2013; Universidade Federal do Rio de Janeiro</institution>, <addr-line>Rio de Janeiro, Rio de Janeiro</addr-line>,&#xa0;<country>Brazil</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Laborat&#xf3;rio Interdisciplinar de Pesquisas M&#xe9;dicas, Instituto Oswaldo Cruz, Funda&#xe7;&#xe3;o Oswaldo Cruz</institution>, <addr-line>Rio de Janeiro</addr-line>,&#xa0;<country>Brazil</country>
</aff>
<aff id="aff5">
<sup>5</sup>
<institution>N&#xfa;cleo de Doen&#xe7;as Infecciosas &#x2013; Universidade Federal do Esp&#xed;rito Santo</institution>, <addr-line>Vit&#xf3;ria, Esp&#xed;rito Santo</addr-line>,&#xa0;<country>Brazil</country>
</aff>
<aff id="aff6">
<sup>6</sup>
<institution>Disciplina de Parasitologia, Faculdade de Ci&#xea;ncias M&#xe9;dicas, UERJ</institution>, <addr-line>Rio de Janeiro, RJ</addr-line>,&#xa0;<country>Brazil</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Diego Luis Costa, University of S&#xe3;o Paulo, Brazil</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Lucas P. Carvalho, Gon&#xe7;alo Moniz Institute (IGM), Brazil</p>
<p>La&#xed;s Amorim Sacramento, University of Pennsylvania, United States</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Herbert Leonel de Matos Guedes, <email xlink:href="mailto:herbert@micro.ufrj.br">herbert@micro.ufrj.br</email>; <email xlink:href="mailto:herbert@ioc.fiocruz.br">herbert@ioc.fiocruz.br</email>
</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>04</day>
<month>08</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="collection">
<year>2025</year>
</pub-date>
<volume>16</volume>
<elocation-id>1621781</elocation-id>
<history>
<date date-type="received">
<day>01</day>
<month>05</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>10</day>
<month>06</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2025 Da-Rocha, Dos-Santos, Bittencourt, De-Almeida, Manh&#xe3;es, Praxedes, Romano, da Silva-Junior, da Silva-Gon&#xe7;alves, Oliveira, Covre, Gomes, Da-Cruz, da Fonseca-Martins and de Matos Guedes.</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Da-Rocha, Dos-Santos, Bittencourt, De-Almeida, Manh&#xe3;es, Praxedes, Romano, da Silva-Junior, da Silva-Gon&#xe7;alves, Oliveira, Covre, Gomes, Da-Cruz, da Fonseca-Martins and de Matos Guedes</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Mucosal Leishmaniasis is one of the most aggressive clinical manifestations of <italic>Leishmania</italic> infection disease, characterized by the destruction of nasal and oral tissues. The mechanisms by which this disease occurs are still not well understood due to the lack of effective experimental models. Mucosal leishmaniasis is associated with inflammatory response, especially Th17 response. Based on that, in this work, the immunopathological aspects of the experimental infection of BALB/c mice by <italic>Leishmania amazonensis</italic> in the mucosa site were evaluated as this mice presents high susceptibility with increased Th17 mediated pathology. Three infection modes were performed and compared according to the injection site. Six weeks post infection, mice presented edema in the nasal and premaxillary region, with progressive growth until twelve weeks. The micro-Computerized Tomography and the histology images demonstrated that the parasite inoculation led to destruction of squamous and transitional tissues in NC and NB groups, with several cells harboring amastigotes. Mice infected in the mucosa tissues had higher parasite load and IgG, IgM antibody levels and increased production of cytotoxic mediators such as CD107, granzyme b and perforin, inflammatory cytokines as IFN-&#x3b3;; and IL-17, but lower frequencies of CD4<sup>+</sup> IL-10<sup>+</sup> cells compared to ear dermis. Taken together, our data shows that <italic>L. amazonensis</italic> parasites are more proliferative in nasal mucosa and the infection leads to an increased inflammatory response compared to ear dermis, suggesting an imbalance between the inflammatory and regulatory response in the mucosa as occurs in human  MCL which point this model as an interesting approach to understand some features of the disease immunopathology. Further studies are being performed to understand the Th1-mediated tissue destruction. This study was conducted in accordance with the local legislation and institutional requirements being approved by the Ethics Committee on the Animal Use in Experimentation - under the protocol CEUA No. 133/23 of the Health Sciences Center (CCS) from the University of Rio de Janeiro.</p>
</abstract>
<kwd-group>
<kwd>leishmaniasis</kwd>
<kwd>mucosa</kwd>
<kwd>
<italic>L. amazonensis</italic>
</kwd>
<kwd>BALB/c</kwd>
<kwd>experimental infection</kwd>
</kwd-group>    <contract-num rid="cn001">E-26/200.993/2022</contract-num>    <contract-num rid="cn002">307632/2022-9</contract-num>    <contract-sponsor id="cn001">Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro<named-content content-type="fundref-id">10.13039/501100004586</named-content>
</contract-sponsor>    <contract-sponsor id="cn002">Conselho Nacional de Desenvolvimento Cientifico e Tecnologico<named-content content-type="fundref-id">10.13039/501100003593</named-content>
</contract-sponsor>
<counts>
<fig-count count="7"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="49"/>
<page-count count="14"/>
<word-count count="4582"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Parasite Immunology</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Leishmaniasis is a group of neglected tropical diseases caused by infection by protozoan parasites belonging to the genus <italic>Leishmania</italic>. The disease affects the most deprived populations in the world, being endemic in more than 98 countries, with cases distributed across Asia, Africa, the Middle East, and South and Central America (<xref ref-type="bibr" rid="B1">1</xref>). Estimates suggest that around 1 million new cases of leishmaniasis occur every year globally, with a population of 1 billion people living in areas at risk of contracting the disease (<xref ref-type="bibr" rid="B2">2</xref>). Of the different clinical manifestations of leishmaniasis, mucocutaneous leishmaniasis (MCL) stands out because it can generate a severe deformity, generating destruction of the tissues of the nose, upper lips, palate, pharynx, larynx, perforation of the septum and loss of bone tissue (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>). Mucocutaneous Leishmaniasis (MCL) is a consequence of <italic>Leishmania</italic>&#x2019;s tropism for mucosal tissues, involving the respiratory mucosa of the upper tract and the oral cavity. This clinical manifestation is typically a result of infection with New World species such as <italic>L. braziliensis</italic>, <italic>L. panamensis</italic>, <italic>L. guyanensis</italic> and <italic>L. amazonensis</italic> (<xref ref-type="bibr" rid="B5">5</xref>). It is estimated that 3 to 5% of cases of cutaneous leishmaniasis caused by these species evolve into the mucosal form (<xref ref-type="bibr" rid="B6">6</xref>). The cure rate for MCL treatment is lower compared to LCL (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>), which highlights the importance of a better understanding of development and immune response in this clinical manifestation (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B10">10</xref>).</p>
<p>Therefore, despite being a more severe manifestation and even with a wide range of <italic>Leishmania</italic> species that can cause MCL and capable of infecting small rodents such as hamsters and mice, there is a lack of experimental models for MCL (<xref ref-type="bibr" rid="B5">5</xref>), and the immune response associated with this clinical manifestation is still poorly characterized. Using <italic>Leishmania amazonensis</italic> infection on BALB/c mice that is very susceptible to infection, we hypothesized that the parasite could establish the infection directly to the nose inducing manifestation similar to mucosal leishmaniasis. Previous attempts were made in the literature using subcutaneous infection in the paw leading to mucosal metastasis, however, they are very long (approximately 8 months after infection) diverse (some animals do not develop the disease) and several mice don&#x2019;t survive during the prolonged infection and aging process. It is urgent a model that facilitates the study of mucosal leishmaniasis (<xref ref-type="bibr" rid="B11">11</xref>). In the context of the disease, mucosal leishmaniasis is associated with a Th1, but also a Th17, neutrophil infiltrate immune response (<xref ref-type="bibr" rid="B12">12</xref>). Meanwhile, BALB/c dermal pathology is associated with Th2 (<xref ref-type="bibr" rid="B13">13</xref>) but also with a strong Th17 (<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B15">15</xref>), making BALB/c a model to exploit the role of those immune axis to the pathology of mucosal leishmaniasis. In this way, here in we established a <italic>L. amazonensis</italic> mucosal leishmaniasis mice model using three infections sites to understand the immunopathology of the disease.</p>
</sec>
<sec id="s2">
<title>Methods</title>
<sec id="s2_1">
<title>
<italic>Leishmania</italic> culture</title>
<p>In this work, parasites of the species <italic>L. amazonensis</italic> (MHOM/BR/75/JOSEFA) were used. The promastigotes were maintained in 25cm&#xb2; culture flasks with M199 medium (pH 7.2), supplemented with 10% fetal bovine serum, 5&#xb5;g/mL bovine hemin, 50U/mL penicillin, and 50&#xb5;g/mL streptomycin.</p>
</sec>
<sec id="s2_2">
<title>Animals</title>
<p>Mice from BALB/c lineage, females aged 8&#x2013;12 weeks, were used. The mice came from the Biot&#xe9;rio Central de Camundongos of the Centro de Ci&#xea;ncias da Sa&#xfa;de (CCS) from the Universidade Federal do Rio de Janeiro, mice were maintained under the Protocol of the Ethics Committee on the Use of Experimental Animals No. 133/23 of the CCS.</p>
</sec>
<sec id="s2_3">
<title>Infection and lesion development</title>
<p>The parasites were cultivated until the beginning of the stationary phase. The culture containing the promastigote forms were collected, washed with phosphate buffer saline (PBS); and centrifuged for 10 minutes at 4&#xb0;C at 1000 x G force. After centrifugation, the supernatant was discarded, and the cells were washed with PBS. The procedure was repeated twice. Then the cells were counted and adjusted to a concentration of 2x10<sup>8</sup> parasites/mL. The animals were sedated with ketamine and xylazine and infected with 2x10<sup>6</sup> parasites using Hamilton<sup>&#xae;</sup> syringes coupled with 34G needles. Different infection methods were implemented: intradermal in the ear performed at an angle of 20&#xb0;; Cutaneous Nose, with the inoculum carried out at the apex of the mouse&#x2019;s nose; Septum, with the inoculum occurring in the mouse septum and &#x201c;Nasobasal&#x201d;, with the inoculum being carried out at an angle of 60&#xb0; towards the lower &#x201c;floor&#x201d; part of the nose. The lesion was monitored with photos. Weekly measurements of the mice&#x2019;s ears were taken using Mitutoyo&#x2122; thickness gauges.</p>
</sec>
<sec id="s2_4">
<title>Micro computerized tomography, 3D reconstruction and lesion analysis</title>
<p>Animals were sedated and placed in the LabPET8 Flex Triumph Gamma Medica&#x2122; tomography system at CENABIO, UIPA. The equipment settings included 60kV, 480&#xb5;A, 1024 projections, 8-minute acquisition, and 30x magnification with a 39.46mm field of view, focusing on the snout and mucous membrane. After acquisition, data was reconstructed and analyzed using 3D Slicer&#x2122; software, with the Scissors tool applied to generate the snout area.</p>
</sec>
<sec id="s2_5">
<title>Histology analysis</title>
<p>Tissues from animal snouts were fixed in 4% formaldehyde in PBS for 15 days. Decalcification was performed for 28 days using 10% EDTA. After fixation and decalcification, tissues were dehydrated through a series of ethanol and xylene solutions, then embedded in paraffin. Sections (5&#xb5;m thick) were cut, rehydrated, and stained with Hematoxylin &amp; Eosin (H&amp;E). Tissue processing was done by the Histotechnology Platform at IOC - FIOCRUZ. Histology was performed with n = 5 per group.</p>
</sec>
<sec id="s2_6">
<title>Parasite load quantification</title>
<p>At the end of each experiment, parasite load was assessed using the limiting dilution method (LDA). Animals were euthanized with an overdose of Ketamine and Xylazine, and tissues (snout, nose tip, premaxilla, ear, cervical lymph node, ear lymph node, NALT, and spleen) were collected, weighed, and macerated in 1mL of M199. Serial 1:4 dilutions were made, and the results were plotted. Three experiments (n=3-5) were conducted, with two examining the entire snout and one focusing on segmented parts, 12 weeks post-infection.</p>
</sec>
<sec id="s2_7">
<title>Flow cytometry</title>
<p>Flow cytometric analysis of cells from cervical and ear lymph nodes of infected or na&#xef;ve animals was performed. Tissues were macerated, and cells counted with 0.1% trypan blue dye. 1x10<sup>6</sup> cells were plated in a 96-well plate, centrifuged, and stimulated with PMA (20ng/mL), ionomycin (1&#xb5;g/mL), and monensin (2.5&#xb5;g/mL) in Complete RPMI for 4 hours at 37&#xb0;C. Cells were blocked with anti-FcR, surface stained, fixed using the eBioscience&#x2122; FoxP3 kit, and intracellularly labeled. The samples were analyzed on a BD LSR Fortessa X-20 cytometer. <xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table S1</bold>
</xref> denotes the cytometer configuration. <xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table S2</bold>
</xref> shows the antibodies (BioLegend&#x2122;) used and their concentrations. <xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure S1</bold>
</xref> denotes the performed gating strategy.</p>
</sec>
<sec id="s2_8">
<title>Statistics</title>
<p>Results are represented by Standard Error of the Mean (SEM). Statistical significance was performed by unpaired two tailed Student t test with 95% confidence interval (p&lt;0,05) for the respective data: Lesion profile by tomography, parasite load quantification and cytometry. While One Way ANOVA with 95% interval of confidence (p&lt;0,05) was performed using Tukey post-test, for the ELISA OD Sum data. Statistically significant differences were defined as * for p&lt;0,05; ** for p&lt;0,005; *** for p&lt;0,0005.</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<title>Results</title>
<sec id="s3_1">
<title>Direct inoculation of <italic>Leishmania amazonensis</italic> in nasal mucosa led to injury but the lesion profile depends on the type of inoculum performed</title>
<p>To assess <italic>Leishmania</italic> infection in the nasal mucosa, 2x10<sup>6</sup> promastigotes of <italic>L. amazonensis</italic> were directly inoculated into different nasal sites of mice. After 6 weeks, the Nose Cutaneous (NC) and Nasobasal (NB) groups developed visible lesions with edema and redness (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1A</bold>
</xref>). These lesions progressed and became necrotic by 12 weeks in some cases. The muzzle volume was significantly larger in the NC and NB groups (387mm&#xb3; and 616mm&#xb3;) compared to the Sham group (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1B</bold>
</xref>), resembling the progressive ear infection, which reached 1.8mm in thickness (<xref ref-type="fig" rid="f1">
<bold>Figures&#xa0;1C, D</bold>
</xref>). In contrast, the Septum group showed no visible lesions throughout the study (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1A</bold>
</xref>). These results indicate that nasal inoculation can cause tissue damage, depending on the infection site.</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Nasal mucosa lesion profile. The modes of nasal mucosa inoculation with <italic>L. amazonensis</italic>. Nose cutaneous (NC) group was inoculated in the nostril nose dermis; Septum (ST) was inoculated in the septum tissue, &#x201c;Nasobasal&#x201d; (NB) was inoculated in the nasal floor. In all cases was used an 34G needle. <bold>(A)</bold> Lesion profile of the three groups, during a period of 12 weeks post infection (p.i), showing a continuous development of edema and erythema starting at 6 to 8 weeks for the NC and NB group. ST group does not show any sign of lesion. <bold>(B)</bold> Snout volume quantification 12 weeks p.i (Standard Error of the Mean &#x2013; (SEM)), using micro&#x2013;Computerized Tomography (micro-CT). NC and NB groups have greater volume compared to control groups. <bold>(C)</bold> Ear dermis lesion thickness of mice infected in the ear as an infection control group (SEM). The thickness continuous increases during the experiment reaching around 2.0mm in 12 weeks p.i. <bold>(D)</bold> Representative ear of a mice from control infection group showing edema and erythema. <bold>(B)</bold> Representative data of 3 independent experiments (5 animals per group). <bold>(C)</bold> Data from one experiment 3&#x2013;5 animals per group. <bold>(D)</bold>&#xa0;Representative data from 2 independent experiments 5 animals were used. Statistics: unpaired t-test ** p&lt;0,005.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1621781-g001.tif">
<alt-text content-type="machine-generated">Panel A shows images of a mouse over twelve weeks, focusing on nose cutaneous, septum, and nasobasal areas. Panel B is a bar chart comparing snout segment volume across three groups: CTL, NC, and NB. Panel C is a line graph showing an increase in lesion thickness over eighty-four days. Panel D contains two close-up images of lesions on a mouse snout.</alt-text>
</graphic>
</fig>
</sec>
<sec id="s3_2">
<title>The nasal mucosa model showed a higher parasite load than ear dermis infection.</title>
<p>Parasite load in infected mice ranged from 10<sup>6</sup> to 10<sup>8</sup> parasites per gram of tissue in the Nose Cutaneous (NC) and Nasobasal (NB) groups, while the Septum (ST) group showed only 10<sup>4</sup> parasites, with Only 20% of animals testing positive (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2A</bold>
</xref>). Ear dermis infections had 10<sup>6</sup> parasites per gram (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2B</bold>
</xref>). Parasites were mostly concentrated in the edema sites, such as the nose tip and pre-maxillary regions (<xref ref-type="fig" rid="f2">
<bold>Figures&#xa0;2C, D</bold>
</xref>). Some animals in the NB group had around 10<sup>5</sup> parasites in NALT (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2E</bold>
</xref>). Only one animal in the NC group showed spleen infection (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2F</bold>
</xref>). The cervical lymph nodes of NC and NB mice had 10<sup>6</sup> parasites (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2G</bold>
</xref>), while the ear lymph nodes had 10<sup>5</sup> parasites (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2H</bold>
</xref>). The Septum group showed parasitic load in the cervical lymph node but not the nasal cavity (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2G</bold>
</xref>). These results indicate that mucocutaneous <italic>L. amazonensis</italic> infection leads to a higher parasite content in nasal mucosa infection compared to ear dermis, with the cervical lymph node being the primary draining node.</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Parasite load profile. Profile of parasite load per gram of tissue, of the different groups of infection. NC, ST, NB, ED means respectively to Nose Cutaneous, Septum, &#x201c;Nasobasal&#x201d; and Ear dermis infection groups. The following tissues are represented in the figure: <bold>(A)</bold> Nose = the entire snout containing the nasal tissues; <bold>(B)</bold> Ear; <bold>(C)</bold> Nose Surface = only the visible nose; <bold>(D)</bold> mice premaxillary region; <bold>(E)</bold> Nasal Associated Lymphoid Tissue (NALT); <bold>(F)</bold> Spleen; <bold>(G)</bold> Cervical lymph node; <bold>(H)</bold> auricular lymph node. Parasite load was detected by the limiting dilution method (LDA) carried out at the end of the experiment (approximately 12 weeks of infection). <bold>(A)</bold> Data from 3 independent experiments; <bold>(B&#x2013;D)</bold> 1 independent experiment; and <bold>(E)</bold>, Data from 4 independent experiments; <bold>(G, H)</bold>, 2 independent experiments. N = 5 animals per group. Data represented with the Standard Error of The Mean (SEM). Statistics: unpaired t-test *p &lt; 0,05, ***p &lt; 0,0005.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1621781-g002.tif">
<alt-text content-type="machine-generated">Bar graphs labeled A to H show the number of parasites per gram of tissue in various anatomical sites: Nose, Ear, Nose Surface, Pr&#xe9;-Maxillary, NALT, Spleen, Cervical LN, and Auricular LN. Y-axis represents parasite count on a logarithmic scale. Different samples (NC, ST, NB, ED) display variation in parasite counts, with significant differences marked by asterisks.</alt-text>
</graphic>
</fig>
</sec>
<sec id="s3_3">
<title>Nasal infection induced nasal swelling, but no septum perforation or new nasal cavity formation took place</title>
<p>MicroCT analysis was performed to assess nasal cavity impairment, focusing on the NC and NB groups, as the ST group showed no visible lesions or significant parasite load. NC-infected mice typically had lesions at the nose apex, while NB-infected mice had lesions affecting the mucosa and premaxilla, extending to the upper lips (<xref ref-type="fig" rid="f3">
<bold>Figures&#xa0;3A, B</bold>
</xref>). No nasal cavity enlargement, perforations, or deformation were observed compared to controls (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure S2</bold>
</xref>), but tissue swelling was evident in both NC and NB groups (<xref ref-type="fig" rid="f3">
<bold>Figures&#xa0;3A-D</bold>
</xref>). Axial sections showed noticeable edema on the outer nasal cavity (<xref ref-type="fig" rid="f3">
<bold>Figures&#xa0;3C, D</bold>
</xref>). These results indicate that lesion profiles depend on the inoculation site, mainly affecting the nasal tissues initial portions.</p>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Anatomical and histological profile. <bold>(A, B)</bold> A complete three-dimensional reconstruction of NC and NB mice model respectively. <bold>(C, D)</bold> Coronal Section planes showing edema and partial nose obstruction of NC and NB mice respectively. <bold>(E, F)</bold> Intense inflammatory infiltrate containing infected cells, below the epithelium of NC and NB mice respectively. The red arrows indicate the region of edema, and the white arrows show examples of cells bearing amastigotes. Magnification: <bold>(E)</bold> 1000x and <bold>(F)</bold> 1000x.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1621781-g003.tif">
<alt-text content-type="machine-generated">3D and CT images of a rodent's head show different views. Panel A and B are digital 3D renderings, with B showing a textured surface. Panel C and D are CT scans; C has an arrow indicating a highlighted area. Panels E and F display histological tissue samples with arrows pointing to specific cellular structures.</alt-text>
</graphic>
</fig>
</sec>
<sec id="s3_4">
<title>Nasal infection promoted destruction and deconfiguration of squamous and transitional tissues</title>
<p>Histological analysis of the nasal cavity revealed significant inflammation and parasite presence. In the NC group, edema with a neutrophilic infiltrate and vacuolated macrophages containing amastigotes was observed (<xref ref-type="fig" rid="f3">
<bold>Figures&#xa0;3E</bold>
</xref>, <xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure S3</bold>
</xref>), along with respiratory epithelium loss (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure S4B</bold>
</xref>), and parasitized macrophages near cartilage (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure S4E</bold>
</xref>). In the NB group, similar edema and neutrophil infiltration were seen, with many parasitized macrophages (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3F</bold>
</xref>). Respiratory epithelium showed slight morphological changes, including cellular stress and detachment (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figures S4C, F</bold>
</xref>). These findings indicate that <italic>Leishmania</italic> infection impacts the inner nasal mucosa in this model.</p>
</sec>
<sec id="s3_5">
<title>Nasal mucosa infection produced higher systemic antibodies titers compared to ear dermis infection</title>
<p>To assess immune responses to different nasal mucosa infections by <italic>Leishmania</italic>, we measured antibody levels. The NC group showed the highest IgM, IgG, and IgG1 levels, followed by NB and ED (<xref ref-type="fig" rid="f4">
<bold>Figures&#xa0;4A-F</bold>
</xref>). IgG2a and IgG2b were highest in NB, then NC (<xref ref-type="fig" rid="f4">
<bold>Figures&#xa0;4G-J</bold>
</xref>). Overall, NC and NB had stronger antibody responses than ED, while ST had the lowest. These findings suggest mucocutaneous infection triggers a stronger humoral response than ear dermis infection, with antibody profiles varying by inoculation site.</p>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>Systemic antibodies infection profile. Systemic antibodies responses in the different infected groups. <bold>(A, C, E, G, I)</bold> Ig titration using four dilutions, represented by O.D. 600 absorbance measurements (Standard Error of The Mean (SEM)). <bold>(B, D, F, H, J)</bold> Ig O.D. Sum from each animal and groups. NC groups produce more IgM, total IgG and IgG1, while NB mode of infection have more IgG2a and IgG2b. NC, ST, NB, ED groups represented by square; triangle; inverse triangle and diamond respectively. Statistics: One-way ANOVA; *p&lt;0,05; **p&lt;0,005; ***p&lt;0,0005.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1621781-g004.tif">
<alt-text content-type="machine-generated">Graphs display optical density (OD) measurements for IgM, IgG, IgG1, IgG2a, and IgG2b at various dilutions. Line graphs on the left show decreasing OD with increasing dilution. Bar graphs on the right compare OD sum for groups labeled NC, ST, NB, and ED, with statistical significance denoted by asterisks.</alt-text>
</graphic>
</fig>
</sec>
<sec id="s3_6">
<title>Cytotoxic and effector CD4<sup>+</sup> and CD8<sup>+</sup> T cells from draining lymph nodes were increased in NC, however, CD4<sup>+</sup> T cells producing IL-10 were impaired in nasal mucosa infection</title>
<p>Flow cytometry of draining lymph nodes showed reduced CD4+ T cell frequency in the ED group but not in nasal infections. The NC and NB groups had increased total CD4+ T cells (<xref ref-type="fig" rid="f5">
<bold>Figures&#xa0;5A, E</bold>
</xref>) and higher numbers of cells expressing cytotoxic markers (CD107a, granzyme B, perforin) across NC, NB, and ED groups (<xref ref-type="fig" rid="f5">
<bold>Figures&#xa0;5B-D</bold>
</xref>), despite unchanged frequencies (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figures S6</bold>
</xref>-<xref ref-type="supplementary-material" rid="SM1">
<bold>S8</bold>
</xref>).</p>
<fig id="f5" position="float">
<label>Figure&#xa0;5</label>
<caption>
<p>CD4+ T cells cytotoxic and effector profile. <bold>(A-D)</bold> The cytotoxic profile of T helper lymphocytes was measured by the expression of CD107a, Granzyme B and Perforin. <bold>(A)</bold> Cervical and auricular lymph nodes total Lymphocytes counts are shown in logarithmic scale; <bold>(B)</bold> total cells expressing CD107a, <bold>(C)</bold> Granzyme B; <bold>(D)</bold> Perforin. <bold>(E-H)</bold> The effector profile of T helper lymphocytes was measured by the expression of IL-10, IL-17 and IFN-&#x3b3;. <bold>(E)</bold> Cervical and auricular lymph nodes total lymphocytes counts are shown in logarithmic scale; <bold>(F)</bold> total cells expressing IFN-&#x3b3;, <bold>(G)</bold> IL-17; <bold>(H)</bold> IL-10. Data accumulative of two independent experiments (3&#x2013;6 animals per group). Statistics: plot with Standard Error of The Mean (SEM), t-test was used for all groups and samples *p&lt;0,05, **&lt;0,005, ***p&lt;0,0005 ****p&lt;0,00005.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1621781-g005.tif">
<alt-text content-type="machine-generated">Bar graphs depicting data on TCR&#x3b2;+ CD4+ cells across cervical and auricular lymph nodes (LN) under various conditions labeled CTL, NC, ST, NB, and OR. Panels A to H represent different cellular markers or conditions, with statistical significance indicated by asterisks for comparisons. Data shows variances in cell counts and markers such as CD107a, GzmB, Perforin, IFN&#x3b3;, IL17, and IL10.</alt-text>
</graphic>
</fig>
<p>Although frequencies remained unchanged (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figures S9</bold>
</xref>, <xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figures S10</bold>
</xref>), total IFN-&#x3b3;<sup>+</sup> (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5F</bold>
</xref>) and IL-17<sup>+</sup> (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5G</bold>
</xref>) cells increased in NC, NB, and ED groups. CD4+ IL-10+ T cells increased only in the ED group (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5H</bold>
</xref>), with lower IL-10-producing CD4<sup>+</sup> T cell frequencies in nasal infections compared to ED (<xref ref-type="fig" rid="f6">
<bold>Figures&#xa0;6A, B</bold>
</xref>), highlighting distinct expansion dynamics between nasal and dermal infections.</p>
<fig id="f6" position="float">
<label>Figure&#xa0;6</label>
<caption>
<p>CD4+ T cells IL-10+ is impaired. The IL-10 producing CD4<sup>+</sup> T cells was measured and the frequency is shown. <bold>(A)</bold> Pseudocolor dot plot showing the representative animals of each group. <bold>(B)</bold> Frequency plot from cervical and auricular lymph nodes from infected animals vs controls. Data accumulative of two independent experiments (3&#x2013;6 animals per group). Statistics: plot with Standard Error of The Mean (SEM), t-test was used for all groups and samples **&lt;0,005.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1621781-g006.tif">
<alt-text content-type="machine-generated">Flow cytometry plots (A) and bar graphs (B) showing percentages of TCR&#x3b2;&#x207a; CD4&#x207a; IL10&#x207a; cells. Plots display different groups: CTL, NC, ST, NB, ED, and FMO. Bar graphs illustrate cervical and auricular lymph nodes data with significant differences marked by asterisks.</alt-text>
</graphic>
</fig>
<p>We analyzed whether changes in CD4+ IL-10+ T cells were linked to CD4<sup>+</sup> CD25+ FoxP3+ Tregs. Treg numbers increased in NC, NB, and ED groups without frequency changes (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure S11</bold>
</xref>). Similar trends were observed for CD25- FoxP3+, CD25+ FoxP3-, and CD25- FoxP3- cells (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figures S12</bold>
</xref>-<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure S14</bold>
</xref>), indicating the IL-10 reduction is unrelated to regulatory T cell frequency.</p>
<p>We also analyzed CD8<sup>+</sup> T lymphocytes during mucosal infections. NC and NB groups showed an expansion in total CD8<sup>+</sup> T cells (<xref ref-type="fig" rid="f7">
<bold>Figures&#xa0;7A, E</bold>
</xref>) with frequencies similar to CD4<sup>+</sup> T cells (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure S15</bold>
</xref>). Cytotoxic CD8<sup>+</sup> T cells markers increased in NC, NB, and ED groups (<xref ref-type="fig" rid="f7">
<bold>Figures&#xa0;7B-D</bold>
</xref>), with NC showing higher CD8<sup>+</sup> Perforin<sup>+</sup> frequency (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure S18</bold>
</xref>), nut no frequency changes to CD107a and Granzyme B respectively (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure S16</bold>
</xref>, <xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure S17</bold>
</xref>). There were no IFN-&#x3b3;<sup>+</sup> CD8<sup>+</sup> significant changes in frequency (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7F</bold>
</xref>) or number (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure S19</bold>
</xref>). IL-17<sup>+</sup> CD8<sup>+</sup> T cells increased in NB and ED groups (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7G</bold>
</xref>) without frequency changes (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figures S20</bold>
</xref>). CD8<sup>+</sup> IL-10<sup>+</sup> T cells showed no numerical change (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7H</bold>
</xref>), but frequency decreased in mucosa-infected and ED groups (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure S21</bold>
</xref>).</p>
<fig id="f7" position="float">
<label>Figure&#xa0;7</label>
<caption>
<p>Cytotoxic and effector profile of CD8<sup>+</sup> T cells. <bold>(A-D)</bold> The cytotoxic profile of T helper lymphocytes was measured by the expression of CD107a, Granzyme B and Perforin. <bold>(A)</bold> Cervical and auricular lymph nodes total Lymphocytes counts are shown in logarithmic scale; <bold>(B)</bold> total cells expressing CD107a, <bold>(C)</bold> Granzyme B; <bold>(D)</bold> Perforin. <bold>(E-H)</bold> The effector profile of T helper lymphocytes was measured by the expression of IL-10, IL-17 and IFN-&#x3b3;. <bold>(E)</bold> Cervical and auricular lymph nodes total lymphocytes counts are shown in logarithmic scale; <bold>(F)</bold> total cells expressing IFN-&#x3b3;, <bold>(G)</bold> IL-17; <bold>(H)</bold> IL-10. Data accumulative of two independent experiments (3&#x2013;6 animals per group). Statistics: plot with Standard Error of The Mean (SEM), t-test was used for all groups and samples * p&lt;0,05, **&lt;0,005, ***&lt;0,0005.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1621781-g007.tif">
<alt-text content-type="machine-generated">Bar graphs display various metrics related to TCR&#x3b2;&#x207a; CD8&#x207a; cells in cervical and auricular lymph nodes. Data are categorized by conditions labeled CTL, NC, ST, NB, and OR. Significant statistical differences are indicated with asterisks. Metrics include CD107a, GzmB, Perforin, IFN&#x3b3;, IL17, and IL10. Each panel has separate graphs for cervical (left) and auricular (right) lymph nodes, highlighting differences and statistical significance across different conditions, denoted by brackets and asterisks.</alt-text>
</graphic>
</fig>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<title>Discussion</title>
<p>Mucocutaneous Leishmaniasis (MCL) causes severe tissue damage in nasal, oral, and pharyngeal mucosa, leading to edema and erythema in affected areas (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B5">5</xref>). In our mouse model, the NC and NB groups developed visible edema and erythema by week 6, progressing over time. Lesions in the NC group formed at the nose tip and extended dorsally, resembling the experimental mucosal leishmaniasis in dogs and hamsters (<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B17">17</xref>). In the NB group, lesions spread to the upper lips and premaxilla, mimicking clinical features of human MCL (<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B19">19</xref>).</p>
<p>Some animals developed necrotic lesions after 12 weeks of infection. While <italic>L. amazonensis</italic> typically causes non-necrotizing lesions in BALB/c mice resembling diffuse cutaneous leishmaniasis in humans (<xref ref-type="bibr" rid="B20">20</xref>). Similar variation in infection sites was observed with <italic>Leishmania major</italic> (<xref ref-type="bibr" rid="B21">21</xref>), possibly linked to site-specific microbiota. Nasal microbiota, including <italic>Staphylococcus</italic> and <italic>Streptococcus</italic> species (<xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B23">23</xref>), may exacerbate tissue damage by recruiting neutrophils and CD8 IL-17+ cells during infection (<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B25">25</xref>).</p>
<p>Mucosal leishmaniasis in humans often affects septa, cartilage, and nasal cavities, with occasional bone destruction visible via computed tomography (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B26">26</xref>&#x2013;<xref ref-type="bibr" rid="B28">28</xref>). In this study, microCT revealed edema in the nasal and premaxilla regions of NC and NB groups. Histopathology showed dense cellular infiltrates and infected cells near cartilage and the nasal mucosa, with respiratory epithelium changes, consistent with previous findings (<xref ref-type="bibr" rid="B11">11</xref>).</p>
<p>Despite MCL caused by <italic>Leishmania braziliensis</italic> typically shows fewer parasites at the site than cutaneous leishmaniasis (<xref ref-type="bibr" rid="B29">29</xref>), our model NC and NB groups had higher parasite loads, in the draining lymph nodes and showing also infected cells in nasal mucosa. This may reflect <italic>L. amazonensis</italic> characteristics, which produce higher parasite loads than <italic>L. braziliensis</italic> in mice (<xref ref-type="bibr" rid="B30">30</xref>), and as evidenced by the case of MCL caused by <italic>L. amazonensis</italic>, where parasite amastigotes were described as easily visualized in H&amp;E sections (<xref ref-type="bibr" rid="B31">31</xref>). Unlike previous models focusing on nasal infection (<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B33">33</xref>), this study uniquely examined infections within the nasal mucosa cavity, revealing that the inoculum site significantly influences lesion severity and parasite load across NC, ST, and NB groups. Necrosis was observed in some animals, a feature absents in other models (<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B33">33</xref>). Mucosal infections showed clinical aspects similar to, or more severe than cutaneous ear lesions, aligning with findings in <italic>Leishmania panamensis</italic>-infected hamsters (<xref ref-type="bibr" rid="B17">17</xref>). While other models required approximately 8 months to develop lesions (<xref ref-type="bibr" rid="B11">11</xref>), this approach shortened progression to 6&#x2013;8 weeks. Future studies could compare axenic amastigote infections, given their higher virulence and differing proliferation kinetics from promastigotes (<xref ref-type="bibr" rid="B34">34</xref>, <xref ref-type="bibr" rid="B35">35</xref>).</p>
<p>MCL severity correlates with higher anti-<italic>Leishmania</italic> IgG levels (<xref ref-type="bibr" rid="B36">36</xref>). In our model, mucosal infections (NC and NB) produced more IgM and IgGs than dermal infections, the high antibody levels produced by the mucosal infection compared to dermis can be interpreted as an increased inflammatory response that may contribute to the severity of pathology. Interesting, the mucosal infection site is contributing to the type of immune response with NC favoring IgG1 (Th2 response) and NB favoring IgG2a (Th1 response), according to the antibody dichotomy (<xref ref-type="bibr" rid="B37">37</xref>).</p>
<p>To compare nasal mucosa infections with human MCL, we performed flow cytometry on lymph node cells. Mucosal infection (NC and NB) increased CD4+ and CD8+ T cells expressing cytotoxic markers (CD107a, Granzyme B, Perforin) and IL-17, with less IFN-&#x3b3;, but no increase in IL-10-expressing cells, unlike the ED group. In MCL, CD4+ T cells produce high IFN-&#x3b3; and TNF-&#x3b1;, with elevated Th17 responses that recruit neutrophils and cause tissue damage (<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B39">39</xref>). MCL also shows higher granzyme A-expressing cells, linked to greater damage (<xref ref-type="bibr" rid="B34">34</xref>), with a lower IL-10 receptor expression, despite normal IL-10 expression (<xref ref-type="bibr" rid="B39">39</xref>). Our data suggests a similar imbalance between cytotoxic and regulatory responses, with reduced IL-10+ T cells and increased IL-17+ T cells potentially contributing to severity, as IL-10 limits Th17-mediated pathology in experimental leishmaniasis (<xref ref-type="bibr" rid="B40">40</xref>).</p>
<p>The overall IL-10 production by T cells is important to protect against excessive inflammation and damage during the peak of infection for <italic>Leishmania mexicana</italic> and <italic>L. major</italic> (<xref ref-type="bibr" rid="B40">40</xref>, <xref ref-type="bibr" rid="B41">41</xref>). Tregs (CD4<sup>+</sup> CD25<sup>+</sup> FoxP3<sup>+</sup> T cells) and Tr1 (CD4<sup>+</sup> CD25<sup>-</sup> FoxP3<sup>-</sup> IL-10<sup>+</sup>) are the most important subsets of T cells that provide IL-10 during immune-responses (<xref ref-type="bibr" rid="B42">42</xref>). In the <italic>L. amazonensis</italic> mice infection, the CD4<sup>+</sup> CD25<sup>+</sup> T cells can contribute to parasite control decreasing the inflammatory response (<xref ref-type="bibr" rid="B43">43</xref>). Furthermore, CD4<sup>+</sup> CD25<sup>+</sup> FoxP3<sup>+</sup> T cells are also implicated to reduce inflammation and parasite load in BALB/c mice infection by <italic>Leishmania panamensis</italic> (<xref ref-type="bibr" rid="B44">44</xref>). Moreover, on visceral leishmaniasis mice model, the regulatory T cells had no effect on <italic>Leishmania donovani</italic> parasite proliferation but were able to reduce tissue damage (<xref ref-type="bibr" rid="B45">45</xref>). However, the IL-10 production by T cells is also frequently linked to parasite persistence and in some circumstances an increased pathology. The IL-10 production by CD4<sup>+</sup> CD25<sup>-</sup> FoxP3<sup>-</sup> IL-10<sup>+</sup> T cells in a Th1 environment is important for the lesional persistence of <italic>L. major</italic> (Seidman strain) and <italic>L. mexicana</italic> (<xref ref-type="bibr" rid="B41">41</xref>, <xref ref-type="bibr" rid="B46">46</xref>), while for the <italic>L. major</italic> (Friedlin) that causes a self-healing pathology, the IL-10 production by CD4<sup>+</sup> CD25<sup>+</sup> FoxP3<sup>+</sup> Tregs prevents the sterile cure (<xref ref-type="bibr" rid="B47">47</xref>). In our model, we can hypothesize that the inflammatory response of mucosal sites is exacerbated by the absence of T cell IL-10 production that is not contributing to the parasite control, instead it is favoring the recruitment of host cells for parasite replication and increasing tissue damage.</p>
<p>Taken together, <italic>L. amazonensis</italic> infection in BALB/c mice induces an immune response that reflects some aspects of the human MCL, with increased cytotoxic and effector cells but a compromised regulatory response. However, our studies didn&#x2019;t find some MCL features like cavity formation, septal perforations, and bone destruction, possibly due to parasite species or host lineage differences, or the shortened experimental period compared to human pathology (<xref ref-type="bibr" rid="B28">28</xref>). To address this, ongoing research is being performed with C57BL/6 strain for a stronger Th1 response (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B48">48</xref>). We also are planning to test the <italic>L. braziliensis</italic> hamster model for its higher susceptibility for this species (<xref ref-type="bibr" rid="B49">49</xref>). As NC and NB sites differed in some characteristics, we believe that the combination of these inoculum sites may better represent the full mucosal leishmaniasis profile in mice. More studies are needed to confirm the lymphocyte profile in the mucosal site.</p>
<p>In conclusion, when infected directly at nasal mucosa, <italic>L. amazonensis</italic> parasites are more proliferative and lead to an increased inflammatory response compared to ear dermis infection, which can be associated with the IL-10 impairment related to the immunopathology of MCL.</p>
</sec>
</body>
<back>
<sec id="s5" sec-type="data-availability">
<title>Data availability statement</title>
<p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p>
</sec>
<sec id="s6" sec-type="ethics-statement">
<title>Ethics statement</title>
<p>This study was conducted in accordance with the local legislation and institutional requirements being approved by the Ethics Committee on the Animal Use in Experimentation - under the protocol CEUA No. 133/23 of the Health Sciences Center (CCS) from the University of Rio de Janeiro.</p>
</sec>
<sec id="s7" sec-type="author-contributions">
<title>Author contributions</title>
<p>AD-R: Conceptualization, Methodology, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing, Data curation, Formal analysis, Investigation, Project administration. JD: Conceptualization, Investigation, Writing &#x2013; review &amp; editing, Supervision. IB: Investigation, Writing &#x2013; review &amp; editing. DD-A: Investigation, Writing &#x2013; review &amp; editing. NM: Investigation, Writing &#x2013; review &amp; editing. HP: Investigation, Writing &#x2013; review &amp; editing. JR: Investigation, Writing &#x2013; review &amp; editing. ES-J: Writing &#x2013; review &amp; editing, Formal analysis. AS-G: Writing &#x2013; review &amp; editing, Methodology. MO: Methodology, Writing &#x2013; review &amp; editing. LC: Resources, Writing &#x2013; review &amp; editing, Validation. DDO: Resources, Validation, Writing &#x2013; review &amp; editing. AD-C: Resources, Validation, Writing &#x2013; review &amp; editing. AF-M: Resources, Writing &#x2013; review &amp; editing, Formal analysis, Investigation, Methodology. HDM: Investigation, Writing &#x2013; review &amp; editing, Conceptualization, Funding acquisition, Methodology, Resources, Supervision, Writing &#x2013; original draft.</p>
</sec>
<sec id="s8" sec-type="funding-information">
<title>Funding</title>
<p>The author(s) declare that financial support was received for the research and/ or publication of this article. This work was supported by Fundac&#x327;&#xe3;o de Amparo &#xe0; Pesquisa Estado do Rio de Janeiro &#x2013; FAPERJ Process E-26/200.770/2022 and CNE: 200.993/2022. Conselho Nacional de Desenvolvimento Cientifico e Tecnol&#xf3;gico (CNPQ - Process  PQ1D307632/2022-9).</p>
</sec>
<ack>
<title>Acknowledgments</title>
<p>We would like to acknowledge the Centro Nacional de Bioimagem (CENABIO) for the equipment and technical support in tomography analysis. We would also like to acknowledge the Platform of Histotechnology (FIOCRUZ-RJ) for the processing of histology samples.</p>
</ack>
<sec id="s9" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
<p>The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.</p>
</sec>
<sec id="s10" sec-type="ai-statement">
<title>Generative AI statement</title>
<p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p>
</sec>
<sec id="s11" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s12" sec-type="supplementary-material">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2025.1621781/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fimmu.2025.1621781/full#supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="Image1.pdf" id="SM1" mimetype="application/pdf"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mann</surname> <given-names>S</given-names>
</name>
<name>
<surname>Frasca</surname> <given-names>K</given-names>
</name>
<name>
<surname>Scherrer</surname> <given-names>S</given-names>
</name>
<name>
<surname>Henao-Mart&#xed;nez</surname> <given-names>AF</given-names>
</name>
<name>
<surname>Newman</surname> <given-names>S</given-names>
</name>
<name>
<surname>Ramanan</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>A review of leishmaniasis: current knowledge and future directions</article-title>. <source>Curr Trop Med Rep (Internet).</source> (<year>2021</year>) <volume>8</volume>:<fpage>1</fpage>&#x2013;<lpage>12</lpage>. <uri xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7966913/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7966913/</uri>., PMID: <pub-id pub-id-type="pmid">33747716</pub-id></citation></ref>
<ref id="B2">
<label>2</label>
<citation citation-type="book">
<person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group>. <source>Leishmaniasis</source>. <publisher-name>Whoint</publisher-name> (<year>2022</year>). Available at: <uri xlink:href="https://www.who.int/news-room/fact-sheets/detail/leishmaniasis">https://www.who.int/news-room/fact-sheets/detail/leishmaniasis</uri> (Accessed <access-date>June 30, 2022</access-date>).</citation></ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lessa</surname> <given-names>MM</given-names>
</name>
<name>
<surname>HA</surname> <given-names>L</given-names>
</name>
<name>
<surname>Castro</surname> <given-names>TWN</given-names>
</name>
<name>
<surname>Oliveira</surname> <given-names>A</given-names>
</name>
<name>
<surname>Scherifer</surname> <given-names>A</given-names>
</name>
<name>
<surname>Machado</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Mucosal leishmaniasis: epidemiological and clinical aspects</article-title>. <source>Braz J Otorhinolaryngology.</source> (<year>2007</year>) <volume>73</volume>:<page-range>843&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/s1808-8694(15)31181-2</pub-id>, PMID: <pub-id pub-id-type="pmid">18278231</pub-id></citation></ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goto</surname> <given-names>H</given-names>
</name>
<name>
<surname>Lindoso</surname> <given-names>JAL</given-names>
</name>
</person-group>. <article-title>Cutaneous and mucocutaneous leishmaniasis</article-title>. <source>Infect Dis Clinics North America.</source> (<year>2012</year>) <volume>26</volume>:<fpage>293</fpage>&#x2013;<lpage>307</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.idc.2012.03.001</pub-id>, PMID: <pub-id pub-id-type="pmid">22632640</pub-id></citation></ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Strazzulla</surname> <given-names>A</given-names>
</name>
<name>
<surname>Cocuzza</surname> <given-names>S</given-names>
</name>
<name>
<surname>Pinzone</surname> <given-names>MR</given-names>
</name>
<name>
<surname>Postorino</surname> <given-names>MC</given-names>
</name>
<name>
<surname>Cosentino</surname> <given-names>S</given-names>
</name>
<name>
<surname>Serra</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Mucosal leishmaniasis: an underestimated presentation of a neglected disease</article-title>. <source>BioMed Res Int (Internet)</source>. (<year>2013</year>) <volume>2013</volume>. <uri xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3703408/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3703408/</uri>., PMID: <pub-id pub-id-type="pmid">23853773</pub-id></citation></ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Handler</surname> <given-names>MZ</given-names>
</name>
<name>
<surname>Patel</surname> <given-names>PA</given-names>
</name>
<name>
<surname>Kapila</surname> <given-names>R</given-names>
</name>
<name>
<surname>Al-Qubati</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Schwartz</surname> <given-names>RA</given-names>
</name>
</person-group>. <article-title>Cutaneous and mucocutaneous leishmaniasis: Clinical perspectives</article-title>. <source>J Am Acad Dermatol (Internet).</source> (<year>2015</year>) <volume>73</volume>:<fpage>897</fpage>&#x2013;<lpage>908</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jaad.2014.08.051</pub-id>., PMID: <pub-id pub-id-type="pmid">26568335</pub-id></citation></ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cincur&#xe1;</surname> <given-names>C</given-names>
</name>
<name>
<surname>de Lima</surname> <given-names>CMF</given-names>
</name>
<name>
<surname>Machado</surname> <given-names>PRL</given-names>
</name>
<name>
<surname>Oliveira-Filho</surname> <given-names>J</given-names>
</name>
<name>
<surname>Glesby</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Lessa</surname> <given-names>MM</given-names>
</name>
<etal/>
</person-group>. <article-title>Mucosal leishmaniasis: A Retrospective Study of 327 Cases from an Endemic Area of Leishmania (Viannia) Braziliensis</article-title>. <source>Am J Trop Med Hygiene (Internet).</source> (<year>2017</year>) <volume>97</volume>:<page-range>761&#x2013;6</page-range>. <uri xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5590558/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5590558/</uri>., PMID: <pub-id pub-id-type="pmid">28722607</pub-id></citation></ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martins</surname> <given-names>SS</given-names>
</name>
<name>
<surname>Barroso</surname> <given-names>DH</given-names>
</name>
<name>
<surname>Rodrigues</surname> <given-names>BC</given-names>
</name>
<name>
<surname>da Motta</surname> <given-names>JdOC</given-names>
</name>
<name>
<surname>Freire</surname> <given-names>GSM</given-names>
</name>
<name>
<surname>Pereira</surname> <given-names>LIdA</given-names>
</name>
<etal/>
</person-group>. <article-title>A pilot randomized clinical trial: oral miltefosine and pentavalent antimonials associated with pentoxifylline for the treatment of american tegumentary leishmaniasis</article-title>. <source>Front Cell Infection Microbiol (Internet).</source> (<year>2021</year>) <volume>11</volume>:<elocation-id>700323</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fcimb.2021.700323</pub-id>, PMID: <pub-id pub-id-type="pmid">34277476</pub-id></citation></ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sampaio</surname> <given-names>RNR</given-names>
</name>
<name>
<surname>Silva</surname> <given-names>JSFe</given-names>
</name>
<name>
<surname>Paula</surname> <given-names>CDRd</given-names>
</name>
<name>
<surname>Porto</surname> <given-names>C</given-names>
</name>
<name>
<surname>Motta</surname> <given-names>JdOCd</given-names>
</name>
<name>
<surname>Pereira</surname> <given-names>LIdA</given-names>
</name>
<etal/>
</person-group>. <article-title>A randomized, open-label clinical trial comparing the long-term effects of miltefosine and meglumine antimoniate for mucosal leishmaniasis</article-title>. <source>Rev da Sociedade Bras Medicina Trop</source>. (<year>2019</year>) <volume>52</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.1590/0037-8682-0292-2018</pub-id>, PMID: <pub-id pub-id-type="pmid">30942258</pub-id></citation></ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calvopina</surname> <given-names>M</given-names>
</name>
<name>
<surname>Jijon</surname> <given-names>S</given-names>
</name>
<name>
<surname>Serrano</surname> <given-names>E</given-names>
</name>
<name>
<surname>Kato</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Case report: successful treatment with miltefosine of severe new world mucosal leishmaniasis caused by leishmania guyanensis</article-title>. <source>Am J Trop Med Hygiene.</source> (<year>2020</year>) <volume>103</volume>:<page-range>752&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4269/ajtmh.19-0867</pub-id>, PMID: <pub-id pub-id-type="pmid">32524951</pub-id></citation></ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cupolilo</surname> <given-names>SM</given-names>
</name>
<name>
<surname>Souza</surname> <given-names>F</given-names>
</name>
<name>
<surname>Abreu-Silva</surname> <given-names>AL</given-names>
</name>
<name>
<surname>Calabrese</surname> <given-names>KS</given-names>
</name>
<name>
<surname>Goncalves</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Biological behavior of Leishmania (L.) amazonensis isolated from a human diffuse cutaneous leishmaniasis in inbred strains of mice</article-title>. <source>PubMed. Natl Institutes Health;</source>. (<year>2003</year>) <volume>18</volume>:<page-range>1059&#x2013;65</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.14670/hh-18.1059</pub-id>, PMID: <pub-id pub-id-type="pmid">12973675</pub-id></citation></ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boaventura</surname> <given-names>V</given-names>
</name>
<name>
<surname>Santos</surname> <given-names>CS</given-names>
</name>
<name>
<surname>Ribeiro</surname> <given-names>C</given-names>
</name>
<name>
<surname>de</surname> <given-names>J</given-names>
</name>
<name>
<surname>Santos</surname>
</name>
<name>
<surname>Clar&#xea;ncio</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Human mucosal leishmaniasis: Neutrophils infiltrate areas of tissue damage that express high levels of Th17-related cytokines</article-title>. <source>Eur J Immunol Wiley-Blackwell;</source>. (<year>2010</year>) <volume>40</volume>:<page-range>2830&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/eji.200940115</pub-id>, PMID: <pub-id pub-id-type="pmid">20812234</pub-id></citation></ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sacks</surname> <given-names>D</given-names>
</name>
<name>
<surname>Noben-Trauth</surname> <given-names>N</given-names>
</name>
</person-group>. <article-title>The immunology of susceptibility and resistance to <italic>Leishmania major</italic> in mice</article-title>. <source>Nat Rev Immunol</source>. (<year>2002</year>) <volume>2</volume>:<page-range>845&#x2013;58</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nri933</pub-id>, PMID: <pub-id pub-id-type="pmid">12415308</pub-id></citation></ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lopez Kostka</surname> <given-names>S</given-names>
</name>
<name>
<surname>Dinges</surname> <given-names>S</given-names>
</name>
<name>
<surname>Griewank</surname> <given-names>K</given-names>
</name>
<name>
<surname>Iwakura</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Udey</surname> <given-names>MC</given-names>
</name>
<name>
<surname>von Stebut</surname> <given-names>E</given-names>
</name>
</person-group>. <article-title>IL-17 promotes progression of cutaneous leishmaniasis in susceptible mice</article-title>. <source>J Immunol</source>. (<year>2009</year>) <volume>182</volume>:<page-range>3039&#x2013;46</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/jimmunol.0713598</pub-id>, PMID: <pub-id pub-id-type="pmid">19234200</pub-id></citation></ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dos-Santos</surname> <given-names>JS</given-names>
</name>
<name>
<surname>Firmino-Cruz</surname> <given-names>L</given-names>
</name>
<name>
<surname>Ramos</surname> <given-names>TD</given-names>
</name>
<name>
<surname>Fonseca-Martins</surname> <given-names>AMd</given-names>
</name>
<name>
<surname>Oliveira-Maciel</surname> <given-names>D</given-names>
</name>
<name>
<surname>De-Medeiros</surname> <given-names>JVR</given-names>
</name>
<etal/>
</person-group>. <article-title>Characterization of sv129 mice as a susceptible model to leishmania amazonensis</article-title>. <source>Front Med</source>. (<year>2019</year>) <volume>6</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fmed.2019.00100</pub-id>, PMID: <pub-id pub-id-type="pmid">31192210</pub-id></citation></ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pirmez</surname> <given-names>C</given-names>
</name>
<name>
<surname>Marzochi</surname> <given-names>MCA</given-names>
</name>
<name>
<surname>Coutinho</surname> <given-names>SG</given-names>
</name>
</person-group>. <article-title>Experimental canine mucocutaneous leishmaniasis (Leishmania Braziliensis Braziliensis)</article-title>. <source>Mem&#xf3;rias do Instituto Oswaldo Cruz.</source> (<year>1988</year>) <volume>83</volume>:<page-range>145&#x2013;51</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1590/s0074-02761988000200001</pub-id>, PMID: <pub-id pub-id-type="pmid">2687621</pub-id></citation></ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Osorio</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Melby</surname> <given-names>PC</given-names>
</name>
<name>
<surname>Pirmez</surname> <given-names>C</given-names>
</name>
<name>
<surname>Chandrasekar</surname> <given-names>B</given-names>
</name>
<name>
<surname>Guar&#xed;n</surname> <given-names>N</given-names>
</name>
<name>
<surname>Travi</surname> <given-names>BL</given-names>
</name>
</person-group>. <article-title>The site of cutaneous infection influences the immunological response and clinical outcome of hamsters infected with Leishmania panamensis</article-title>. <source>Parasite Immunol Wiley-Blackwell;</source>. (<year>2003</year>) <volume>25</volume>:<page-range>139&#x2013;48</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1046/j.1365-3024.2003.00615.x</pub-id>, PMID: <pub-id pub-id-type="pmid">12911522</pub-id></citation></ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marsden</surname> <given-names>PD</given-names>
</name>
</person-group>. <article-title>Mucosal leishmaniasis due to Leishmania (Viannia) Braziliensis L(V)b in Tr&#xea;s Bra&#xe7;os, Bahia-Brazil</article-title>. <source>Rev da Sociedade Bras Medicina Tropical.</source> (<year>1994</year>) <volume>27</volume>:<fpage>93</fpage>&#x2013;<lpage>101</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1590/s0037-86821994000200007</pub-id>, PMID: <pub-id pub-id-type="pmid">8073158</pub-id></citation></ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lambertucci</surname> <given-names>JR</given-names>
</name>
<name>
<surname>Coulaud</surname> <given-names>R</given-names>
</name>
<name>
<surname>Cristina</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>Mucosal leishmaniasis. Revista da sociedade brasileira de medicina tropical</article-title>. <source>Braz Soc Trop Medicine;</source>. (<year>2003</year>) <volume>36</volume>:<page-range>307&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1590/S0037-86822003000200017</pub-id>, PMID: <pub-id pub-id-type="pmid">12806470</pub-id></citation></ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>P&#xe9;rez</surname> <given-names>H</given-names>
</name>
<name>
<surname>Arredondo</surname> <given-names>B</given-names>
</name>
<name>
<surname>Gonz&#xe1;lez</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Comparative study of American cutaneous leishmaniasis and diffuse cutaneous leishmaniasis in two strains of inbred mice</article-title>. <source>Infection Immunity.</source> (<year>1978</year>) <volume>22</volume>:<page-range>301&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/iai.22.2.301-307.1978</pub-id>, PMID: <pub-id pub-id-type="pmid">730354</pub-id></citation></ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baldwin</surname> <given-names>TM</given-names>
</name>
<name>
<surname>Elso</surname> <given-names>C</given-names>
</name>
<name>
<surname>Curtis</surname> <given-names>J</given-names>
</name>
<name>
<surname>Buckingham</surname> <given-names>L</given-names>
</name>
<name>
<surname>Handman</surname> <given-names>E</given-names>
</name>
</person-group>. <article-title>The site of <italic>leishmania major</italic> infection determines disease severity and immune responses. Infection and immunity</article-title>. <source>Am Soc Microbiology;</source>. (<year>2003</year>) <volume>71</volume>:<page-range>6830&#x2013;4</page-range>., PMID: <pub-id pub-id-type="pmid">14638769</pub-id></citation></ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bomar</surname> <given-names>L</given-names>
</name>
<name>
<surname>Brugger</surname> <given-names>SD</given-names>
</name>
<name>
<surname>Lemon</surname> <given-names>KP</given-names>
</name>
</person-group>. <article-title>Bacterial microbiota of the nasal passages across the span of human life</article-title>. <source>Curr Opin Microbiol</source>. (<year>2018</year>) <volume>41</volume>:<fpage>8</fpage>&#x2013;<lpage>14</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.mib.2017.10.023</pub-id>, PMID: <pub-id pub-id-type="pmid">29156371</pub-id></citation></ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thangaleela</surname> <given-names>S</given-names>
</name>
<name>
<surname>Sivamaruthi</surname> <given-names>BS</given-names>
</name>
<name>
<surname>Kesika</surname> <given-names>P</given-names>
</name>
<name>
<surname>Bharathi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Chaiyasut</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Nasal microbiota, olfactory health, neurological disorders and aging&#x2014;A review</article-title>. <source>Microorganisms.</source> (<year>2022</year>) <volume>10</volume>:<fpage>1405</fpage>., PMID: <pub-id pub-id-type="pmid">35889124</pub-id></citation></ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borb&#xf3;n</surname> <given-names>TY</given-names>
</name>
<name>
<surname>Scorza</surname> <given-names>BM</given-names>
</name>
<name>
<surname>Clay</surname> <given-names>GM</given-names>
</name>
<name>
<surname>Lima Nobre de Queiroz</surname> <given-names>F</given-names>
</name>
<name>
<surname>Sariol</surname> <given-names>AJ</given-names>
</name>
<name>
<surname>Bowen</surname> <given-names>JL</given-names>
</name>
<etal/>
</person-group>. <article-title>Coinfection with Leishmania major and Staphylococcus aureus enhances the pathologic responses to both microbes through a pathway involving IL-17A</article-title>. <source>PloS Negl Trop Diseases.</source> (<year>2019</year>) <volume>13</volume>:<elocation-id>e0007247</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pntd.0007247</pub-id>, PMID: <pub-id pub-id-type="pmid">31107882</pub-id></citation></ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname> <given-names>TP</given-names>
</name>
<name>
<surname>Carvalho</surname> <given-names>AM</given-names>
</name>
<name>
<surname>Sacramento</surname> <given-names>LA</given-names>
</name>
<name>
<surname>Grice</surname> <given-names>EA</given-names>
</name>
<name>
<surname>Scott</surname> <given-names>P</given-names>
</name>
<name>
<surname>St&#xe4;ger</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Microbiota instruct IL-17A-producing innate lymphoid cells to promote skin inflammation in cutaneous leishmaniasis</article-title>. <source>PloS Pathogens.</source> (<year>2021</year>) <volume>17</volume>:<elocation-id>e1009693</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.ppat.1009693</pub-id>, PMID: <pub-id pub-id-type="pmid">34699567</pub-id></citation></ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rojas-Jaimes</surname> <given-names>J</given-names>
</name>
<name>
<surname>Lescano</surname> <given-names>AG</given-names>
</name>
<name>
<surname>Frischtak</surname> <given-names>HL</given-names>
</name>
<name>
<surname>Arenas</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Case report: mucosal leishmaniasis presenting with nasal septum perforation after almost thirty years</article-title>. <source>Am J Trop Med Hygiene.</source> (<year>2018</year>) <volume>99</volume>:<page-range>327&#x2013;30</page-range>., PMID: <pub-id pub-id-type="pmid">29869609</pub-id></citation></ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bhowate</surname> <given-names>RR</given-names>
</name>
<name>
<surname>Bhargava</surname> <given-names>PA</given-names>
</name>
<name>
<surname>Badki</surname> <given-names>SD</given-names>
</name>
</person-group>. <article-title>Mrunal meshram. Mucosal leishmaniasis involving the nostril and maxillary sinus: A case report</article-title>. <source>Cureus</source>. (<year>2022</year>) <volume>14</volume>:<elocation-id>e30289</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.7759/cureus.30289</pub-id>, PMID: <pub-id pub-id-type="pmid">36381698</pub-id></citation></ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Camargo</surname> <given-names>RA</given-names>
</name>
<name>
<surname>de Nicodemo</surname> <given-names>AC</given-names>
</name>
<name>
<surname>Sumi</surname> <given-names>DV</given-names>
</name>
<name>
<surname>Mello Santiago Gebrim</surname> <given-names>EM</given-names>
</name>
<name>
<surname>Tuon</surname> <given-names>FF</given-names>
</name>
<name>
<surname>de Camargo</surname> <given-names>LM</given-names>
</name>
<etal/>
</person-group>. <article-title>Facial structure alterations and abnormalities of the paranasal sinuses on multidetector computed tomography scans of patients with treated mucosal leishmaniasis</article-title>. <source>PloS Negl Trop Diseases. Public Library Science;</source>. (<year>2014</year>) <volume>8</volume>:<page-range>e3001&#x2013;1</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pntd.0003001</pub-id>, PMID: <pub-id pub-id-type="pmid">25080261</pub-id></citation></ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jara</surname> <given-names>M</given-names>
</name>
<name>
<surname>Adaui</surname> <given-names>V</given-names>
</name>
<name>
<surname>Valencia</surname> <given-names>BM</given-names>
</name>
<name>
<surname>Martinez</surname> <given-names>D</given-names>
</name>
<name>
<surname>Alba</surname> <given-names>M</given-names>
</name>
<name>
<surname>Castrillon</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Real-time PCR assay for detection and quantification of leishmania (Viannia) organisms in skin and mucosal lesions: exploratory study of parasite load and clinical parameters</article-title>. <source>J Clin Microbiol</source>. (<year>2013</year>) <volume>51</volume>:<page-range>1826&#x2013;33</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/JCM.00208-13</pub-id>, PMID: <pub-id pub-id-type="pmid">23554201</pub-id></citation></ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carvalho</surname> <given-names>AK</given-names>
</name>
<name>
<surname>Silveira</surname> <given-names>FT</given-names>
</name>
<name>
<surname>Passero</surname> <given-names>LFD</given-names>
</name>
<name>
<surname>Gomes</surname> <given-names>CMC</given-names>
</name>
<name>
<surname>Corbett</surname> <given-names>CEP</given-names>
</name>
<name>
<surname>Laurente</surname> <given-names>MD.</given-names>
</name>
</person-group> <article-title>Leishmania (V.) Braziliensis and L. (L.) amazonensis promote differential expression of dendritic cells and cellular immune response in murine model</article-title>. <source>Parasite Immunol</source>. (<year>2012</year>) <volume>34</volume>:<fpage>395</fpage>&#x2013;<lpage>403</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/j.1365-3024.2012.01370.x</pub-id>, PMID: <pub-id pub-id-type="pmid">22587683</pub-id></citation></ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sampaio</surname> <given-names>RN</given-names>
</name>
<name>
<surname>Marsden</surname> <given-names>PD</given-names>
</name>
<name>
<surname>Cuentas</surname> <given-names>EAL</given-names>
</name>
<name>
<surname>Cuba</surname> <given-names>CAC</given-names>
</name>
<name>
<surname>Grimaldi</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Leishmania mexicana amazonensis isolated from a patient with fatal mucosal leishmaniasis. Revista da Sociedade Brasileira de Medicina Tropical</article-title>. <source>FapUNIFESP (SciELO);</source>. (<year>1985</year>) <volume>18</volume>:<page-range>273&#x2013;4</page-range>.</citation></ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Teva</surname> <given-names>A</given-names>
</name>
<name>
<surname>Porrozzi</surname> <given-names>R</given-names>
</name>
<name>
<surname>Cupolillo</surname> <given-names>E</given-names>
</name>
<name>
<surname>Pirmez</surname> <given-names>C</given-names>
</name>
<name>
<surname>Mp</surname> <given-names>O-N</given-names>
</name>
<name>
<surname>Grimaldi</surname> <given-names>G</given-names>
</name>
</person-group>. <article-title>Leishmania (Viannia) Braziliensis-induced chronic granulomatous cutaneous lesions affecting the nasal mucosa in the rhesus monkey (Macaca mulatta) model</article-title>. <source>Parasitology.</source> (<year>2003</year>) <volume>127</volume>:<page-range>437&#x2013;47</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1017/s0031182003004037</pub-id>, PMID: <pub-id pub-id-type="pmid">14653533</pub-id></citation></ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cortes</surname> <given-names>S</given-names>
</name>
<name>
<surname>Esteves</surname> <given-names>C</given-names>
</name>
<name>
<surname>Maur&#xed;cio</surname> <given-names>I</given-names>
</name>
<name>
<surname>Maia</surname> <given-names>C</given-names>
</name>
<name>
<surname>Cristov&#xe3;o</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Miles</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>
<italic>In vitro</italic> and <italic>in vivo</italic> behavior of sympatric Leishmania (V.) Braziliensis, L. (V.) Peruviana and their hybrids</article-title>. <source>Parasitology</source>. (<year>2011</year>) <volume>139</volume>:<page-range>191&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1017/s0031182011001909</pub-id>, PMID: <pub-id pub-id-type="pmid">22054424</pub-id></citation></ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mendes Costa</surname> <given-names>D</given-names>
</name>
<name>
<surname>Cec&#xed;lio</surname> <given-names>P</given-names>
</name>
<name>
<surname>Santar&#xe9;m</surname> <given-names>N</given-names>
</name>
<name>
<surname>Cordeiro-da-Silva</surname> <given-names>A</given-names>
</name>
<name>
<surname>Tavares</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Murine infection with bioluminescent Leishmania infantum axenic amastigotes applied to drug discovery</article-title>. <source>Sci Rep</source>. (<year>2019</year>) <volume>9</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41598-019-55474-3</pub-id>, PMID: <pub-id pub-id-type="pmid">31831809</pub-id></citation></ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baek</surname> <given-names>K-H</given-names>
</name>
<name>
<surname>Piel</surname> <given-names>L</given-names>
</name>
<name>
<surname>Rosazza</surname> <given-names>T</given-names>
</name>
<name>
<surname>Prina</surname> <given-names>E</given-names>
</name>
<name>
<surname>Sp&#xe4;th</surname> <given-names>GF</given-names>
</name>
<name>
<surname>No</surname> <given-names>JH</given-names>
</name>
</person-group>. <article-title>Infectivity and drug susceptibility profiling of different leishmania-host cell combinations</article-title>. <source>Pathogens.</source> (<year>2020</year>) <volume>9</volume>:<fpage>393</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/pathogens9050393</pub-id>, PMID: <pub-id pub-id-type="pmid">32443883</pub-id></citation></ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lima</surname> <given-names>CMF</given-names>
</name>
<name>
<surname>Magalh&#xe3;es</surname> <given-names>AS</given-names>
</name>
<name>
<surname>Costa</surname> <given-names>R</given-names>
</name>
<name>
<surname>Barreto</surname> <given-names>CC</given-names>
</name>
<name>
<surname>Machado</surname> <given-names>PRL</given-names>
</name>
<name>
<surname>Carvalho</surname> <given-names>EM</given-names>
</name>
<etal/>
</person-group>. <article-title>High anti-leishmania igG antibody levels are associated with severity of mucosal leishmaniasis</article-title>. <source>Front Cell Infection Microbiol</source>. (<year>2021</year>) <volume>11</volume>., PMID: <pub-id pub-id-type="pmid">33898330</pub-id></citation></ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bretscher</surname> <given-names>PA</given-names>
</name>
</person-group>. <article-title>On the mechanism determining the th1/th2 phenotype of an immune response, and its pertinence to strategies for the prevention, and treatment, of certain infectious diseases</article-title>. <source>Scandinavian J Immunol</source>. (<year>2014</year>) <volume>79</volume>:<page-range>361&#x2013;76</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/sji.12175</pub-id>, PMID: <pub-id pub-id-type="pmid">24684592</pub-id></citation></ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bacellar</surname> <given-names>O</given-names>
</name>
<name>
<surname>Lessa</surname> <given-names>HA</given-names>
</name>
<name>
<surname>Schriefer</surname> <given-names>A</given-names>
</name>
<name>
<surname>Machado</surname> <given-names>P</given-names>
</name>
<name>
<surname>de Jesus</surname> <given-names>AR</given-names>
</name>
<name>
<surname>Dutra</surname> <given-names>WO</given-names>
</name>
<etal/>
</person-group>. <article-title>Up-regulation of th1-type responses in mucosal leishmaniasis patients</article-title>. <source>Infect Immun</source>. (<year>2002</year>) <volume>70</volume>:<page-range>6734&#x2013;40</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/IAI.70.12.6734-6740.2002</pub-id>, PMID: <pub-id pub-id-type="pmid">12438348</pub-id></citation></ref>
<ref id="B39">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Faria</surname> <given-names>DR</given-names>
</name>
<name>
<surname>Gollob</surname> <given-names>KJ</given-names>
</name>
<name>
<surname>Barbosa</surname> <given-names>J</given-names>
</name>
<name>
<surname>Schriefer</surname> <given-names>A</given-names>
</name>
<name>
<surname>Machado</surname> <given-names>PRL</given-names>
</name>
<name>
<surname>Lessa</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Decreased <italic>in situ</italic> expression of interleukin-10 receptor is correlated with the exacerbated inflammatory and cytotoxic responses observed in mucosal leishmaniasis</article-title>. <source>Infection Immunity.</source> (<year>2005</year>) <volume>73</volume>:<page-range>7853&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/IAI.73.12.7853-7859.2005</pub-id>, PMID: <pub-id pub-id-type="pmid">16299275</pub-id></citation></ref>
<ref id="B40">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gonzalez-Lombana</surname> <given-names>C</given-names>
</name>
<name>
<surname>Gimblet</surname> <given-names>C</given-names>
</name>
<name>
<surname>Bacellar</surname> <given-names>O</given-names>
</name>
<name>
<surname>Oliveira</surname> <given-names>WW</given-names>
</name>
<name>
<surname>Passos</surname> <given-names>S</given-names>
</name>
<name>
<surname>Carvalho</surname> <given-names>LP</given-names>
</name>
<etal/>
</person-group>. <article-title>IL-17 mediates immunopathology in the absence of IL-10 following leishmania major infection</article-title>. <source>Langhorne J editor. PloS Pathogens.</source> (<year>2013</year>) <volume>9</volume>:<elocation-id>e1003243</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.ppat.1003243</pub-id>, PMID: <pub-id pub-id-type="pmid">23555256</pub-id></citation></ref>
<ref id="B41">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buxbaum</surname> <given-names>LU</given-names>
</name>
</person-group>. <article-title>Interleukin-10 from T Cells, but Not Macrophages and Granulocytes, Is Required for Chronic Disease in Leishmania mexicana Infection. Infection and Immunity (Internet)</article-title>. <source>Am Soc Microbiol</source>. (<year>2015</year>) <volume>83</volume>:<page-range>1366&#x2013;71</page-range>. <uri xlink:href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4363430/">https://pmc.ncbi.nlm.nih.gov/articles/PMC4363430/</uri>., PMID: <pub-id pub-id-type="pmid">25605773</pub-id></citation></ref>
<ref id="B42">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ng</surname> <given-names>THS</given-names>
</name>
<name>
<surname>Britton</surname> <given-names>GJ</given-names>
</name>
<name>
<surname>Hill</surname> <given-names>EV</given-names>
</name>
<name>
<surname>Verhagen</surname> <given-names>J</given-names>
</name>
<name>
<surname>Burton</surname> <given-names>BR</given-names>
</name>
<name>
<surname>Wraith</surname> <given-names>DC</given-names>
</name>
</person-group>. <article-title>Regulation of adaptive immunity; the role of interleukin-10</article-title>. <source>Front Immunol</source>. (<year>2013</year>) <volume>4</volume>:<elocation-id>3389/fimmu.2013.00129</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2013.00129</pub-id>, PMID: <pub-id pub-id-type="pmid">23755052</pub-id></citation></ref>
<ref id="B43">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ji</surname> <given-names>J</given-names>
</name>
<name>
<surname>Masterson</surname> <given-names>J</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>J</given-names>
</name>
<name>
<surname>Soong</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>CD4+CD25+ Regulatory T Cells Restrain Pathogenic Responses during Leishmania amazonensis Infection</article-title>. <source>J Immunol</source>. (<year>2005</year>) <volume>174</volume>:<page-range>7147&#x2013;53</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/jimmunol.174.11.7147</pub-id>, PMID: <pub-id pub-id-type="pmid">15905558</pub-id></citation></ref>
<ref id="B44">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ehrlich</surname> <given-names>A</given-names>
</name>
<name>
<surname>Castilho</surname> <given-names>TM</given-names>
</name>
<name>
<surname>Goldsmith-Pestana</surname> <given-names>K</given-names>
</name>
<name>
<surname>Chae</surname> <given-names>W-J</given-names>
</name>
<name>
<surname>L M Bothwell</surname> <given-names>A</given-names>
</name>
<name>
<surname>Sparwasser</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>The immunotherapeutic role of regulatory T cells in leishmania (Viannia) panamensis infection</article-title>. <source>J Immunol</source>. (<year>2014</year>) <volume>193</volume>:<page-range>2961&#x2013;70</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/jimmunol.1400728</pub-id>, PMID: <pub-id pub-id-type="pmid">25098291</pub-id></citation></ref>
<ref id="B45">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bunn</surname> <given-names>PT</given-names>
</name>
<name>
<surname>Montes de Oca</surname> <given-names>M</given-names>
</name>
<name>
<surname>de Labastida Rivera</surname> <given-names>F</given-names>
</name>
<name>
<surname>Kumar</surname> <given-names>R</given-names>
</name>
<name>
<surname>Ng</surname> <given-names>SS</given-names>
</name>
<name>
<surname>Edwards</surname> <given-names>CL</given-names>
</name>
<etal/>
</person-group>. <article-title>Distinct Roles for CD4+ Foxp3+ Regulatory T Cells and IL-10&#x2013;Mediated Immunoregulatory Mechanisms during Experimental Visceral Leishmaniasis Caused by Leishmania donovani</article-title>. <source>J Immunol</source>. (<year>2018</year>) <volume>201</volume>:<page-range>3362&#x2013;72</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/jimmunol.1701582</pub-id>, PMID: <pub-id pub-id-type="pmid">30355785</pub-id></citation></ref>
<ref id="B46">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anderson</surname> <given-names>CF</given-names>
</name>
<name>
<surname>Oukka</surname> <given-names>M</given-names>
</name>
<name>
<surname>Kuchroo</surname> <given-names>VJ</given-names>
</name>
<name>
<surname>Sacks</surname> <given-names>D</given-names>
</name>
</person-group>. <article-title>CD4+CD25&#x2013;Foxp3&#x2013; Th1 cells are the source of IL-10&#x2013;mediated immune suppression in chronic cutaneous leishmaniasis</article-title>. <source>J Exp Med</source>. (<year>2007</year>) <volume>204</volume>:<page-range>285&#x2013;97</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1084/jem.20061886</pub-id>, PMID: <pub-id pub-id-type="pmid">17283207</pub-id></citation></ref>
<ref id="B47">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Belkaid</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Piccirillo</surname> <given-names>CA</given-names>
</name>
<name>
<surname>Mendez</surname> <given-names>S</given-names>
</name>
<name>
<surname>Shevach</surname> <given-names>EM</given-names>
</name>
<name>
<surname>Sacks</surname> <given-names>DL</given-names>
</name>
</person-group>. <article-title>CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity</article-title>. <source>Nature.</source> (<year>2002</year>) <volume>420</volume>:<page-range>502&#x2013;7</page-range>.</citation></ref>
<ref id="B48">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tomiotto-Pellissier</surname> <given-names>F</given-names>
</name>
<name>
<surname>Miranda-Sapla</surname> <given-names>MM</given-names>
</name>
<name>
<surname>Silva</surname> <given-names>TF</given-names>
</name>
<name>
<surname>Taciane</surname> <given-names>B</given-names>
</name>
<name>
<surname>Gon&#xe7;alves</surname> <given-names>MD</given-names>
</name>
<name>
<surname>Concato</surname> <given-names>V</given-names>
</name>
<etal/>
</person-group>. <article-title>Murine Susceptibility to Leishmania amazonensis Infection Is Influenced by Arginase-1 and Macrophages at the Lesion Site. Frontiers in Cellular and Infection Microbiology</article-title>. <source>Front Media;</source>. (<year>2021</year>) <volume>11</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fcimb.2021.687633</pub-id>, PMID: <pub-id pub-id-type="pmid">34660334</pub-id></citation></ref>
<ref id="B49">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gomes-Silva</surname> <given-names>A</given-names>
</name>
<name>
<surname>Nogueira</surname> <given-names>RDS</given-names>
</name>
<name>
<surname>Amato</surname> <given-names>VS</given-names>
</name>
<name>
<surname>Amato</surname> <given-names>VS</given-names>
</name>
<name>
<surname>Mattos</surname> <given-names>S</given-names>
</name>
<name>
<surname>Oliveira-Neto</surname> <given-names>MP</given-names>
</name>
<etal/>
</person-group>. <article-title>Can interferon-&#x3b3; and interleukin-10 balance be associated with severity of human <italic>Leishmania (Viannia) Braziliensis</italic> infection</article-title>? <source>Clin Exp Immunol</source>. (<year>2007</year>) <volume>149</volume>:<page-range>440&#x2013;4</page-range>., PMID: <pub-id pub-id-type="pmid">17614975</pub-id></citation></ref>
</ref-list>
</back>
</article>